

Supplementary Table 5. Proportion of individuals with 25(OH)D levels ≥ 20 ng/mL at week 16 according to treatment group in subgroups categorized by the baseline serum 25(OH)D level

Subgroups	Serum 25(OH)D level at week 16	Total (n [%])	Raloxifene monotherapy group (n [%])	Raloxifene/vitamin D combination therapy group (n [%])	P-value ^{a)}
Baseline serum 25(OH)D level <20 ng/mL	<20 ng/mL	15 (53.6)	15 (83.3)	0 (0.0)	0.002
	≥ 20 ng/mL	13 (46.4)	3 (16.7)	10 (100.0)	
	Total	28 (100.0)	18 (100.0)	10 (100.0)	
Baseline serum 25(OH)D level ≥ 20 ng/mL	<20 ng/mL	7 (11.1)	6 (23.1)	1 (2.7)	0.075
	≥ 20 ng/mL	56 (88.9)	20 (76.9)	36 (97.3)	
	Total	63 (100.0)	26 (100.0)	37 (100.0)	

^{a)}Weighted χ^2 test according to the proportion of osteoporosis vs. osteopenia was applied. 25(OH)D, 25-hydroxy-vitamin D.